SUPN Supernus Pharmaceuticals


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 15, 2021, Supernus Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 30, 2021, and a supplement thereto was filed on May 24, 2021. As of the close of business on April 16, 2021, there were 53,018,637 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows:

Proposal 1: Election of Class III Directors, each to serve until the Annual Meeting of the Company in 2024.

NameVotes ForVotes WithheldBroker Non-Votes
Georges Gemayel, Ph.D.35,573,4568,522,4203,122,805
John M. Siebert, Ph.D.43,646,568449,3083,122,805

Proposal 2: Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm for the fiscal year ending December 31, 2021.

Votes ForVotes AgainstAbstainBroker Non-Votes

Proposal 3: To approve, on a non-binding basis, the compensation paid to our named executive officers.

Votes ForVotes AgainstAbstainBroker Non-Votes

Proposal 4: To act upon a proposal to approve and adopt the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan.

Votes ForVotes AgainstAbstainBroker Non-Votes